BioCentury
ARTICLE | Company News

Alnylam, Zeltia deal

November 21, 2011 8:00 AM UTC

Alnylam granted Zeltia's Sylentis S.A. subsidiary a non-exclusive option for a license to develop and commercialize a target-specific synthetic short interfering RNA against an undisclosed target to ...